Radioimmunotherapy of non-Hodgkin lymphomas

Blood

Volumn 101, Issue 2, 2003, Pages 391-398

  Cheson, Bruce D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; RITUXIMAB; TOSITUMOMAB I 131;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER THERAPY; HUMAN; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW;

EID: 0037438974     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-06-1793     Document Type: Review

References (83)

1. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy of relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
2. Davis TA, Grillo-López AJ, White CA, et al. Final report on the safety and efficacy of retreatment with rituximab for patients with non-Hodgkin's lymphoma [abstract]. Blood. 1999;94:88a.
3. 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res. 1999;5:3292S-3303S.
4. Press OW, Eary JF, Badger CC, et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol. 1989;7:1027-1038.
5. Kaminski MS, Fig LM, Zasadny KR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol. 1992;10:1696-1711.
6. DeNardo SJ, DeNardo GL, O'Grady LF, et al. Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody. Antibody Immunoconjugates Radiopharm. 1988;1:17-33.
7. DeNardo GL, DeNardo SJ, O'Grady LF, Levy NB, Adams GP, Mills SL. Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1. Cancer Res. 1990;50:1014s-1016s.
8. DeNardo GL, Lewis JP, DeNardo SJ, O'Grady LF. Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer. 1993; 73:1425-1432.
9. DeNardo GL, DeNardo SJ, Lamborn KR, et al. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131 I-Lym-1 antibody. Cancer Biother Radiopharm. 1998;13:239-254.
10. Scheinberg DA, Straus DJ, Yeh SD, et al. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression. J Clin Oncol. 1990; 8:792-803.
11. Goldenberg DM, Horowitz JA, Sharkey RM, et al. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol. 1991;9:548-564.
12. White CA, Halpern SE, Parker BA, et al. Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies. Blood. 1996;87:3640-3549.
13. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457-470.
14. 111In anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkin's lymphoma (NHL) emphasis on bone marrow (BM) [abstract]. Blood. 1997;90:510a.
15. Wiseman GA, White CA, Stabin M, et al. Therapeutic index of IDEC-Y2B8 radioimmunotherapy: up to 850 fold greater radiation dose to tumor than to normal organs [abstract]. J Clin Oncol. 1999;18:4a.
16. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3793-3803.
17. 90Y Zevalin™ (90)yttrium ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nuclear Med. 2000; 27:766-777.
18. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20: 3262-3269.
19. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453-2463.
20. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin's lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood. 2002;99:4336-4342.
21. Murray JL, Witzig TE, Wiseman GA, et al. Zevalin therapy can convert peripheral blood bcl-2 status from positive to negative in patients with low-grade, follicular or transformed non-Hodgkin's lymphoma (NHL) [abstract]. J Clin Oncol. 2000; 19:22a.
22. Wiseman GA, Witzig TE, Murray JL, et al. Zevalin radioimmunotherapy (RIT) improves quality of life (QOL) in patients with low grade follicular, or transformed non-Hodgkin's lymphoma (LG/F/T NHL) [abstract]. Blood. 2000;96:734a.
23. Flinn IW, Witzig TE, White CA, et al. Zevalin radioimmunotherapy (RIT) regimen is active in heavily pretreated, bulky, rituximab refractory NHL [abstract]. J Clin Oncol. 2001;20:286a.
24. Witzig TE, White CA, Wiseman GA, et al. IDEC-2B8 radioimmunotherapy: responses in patients with splenomegaly [abstract]. Blood. 1998;92: 417a.
25. + transformed (LG/F/T) non-Hodgkin's lymphoma (NHL) [abstract]. J Clin Oncol. 2001;20:286a.
26. Witzig TE, White CA, Gordon LI, et al. Reduceddose Zevalin radioimmunotherapy for relapsed or refractory B-cell non-Hodgkin's lymphoma patients with preexisting thrombocytopenia: report of interim results of a phase II trial [abstract]. Blood. 1999;94:92a.
27. Emmanouilides C, Silverman DA, Leigh BR, Territo M. Successful treatment of Waldenström's macroglobulinemia with Zevalin-based therapy: a case report [abstract]. Blood. 2001;98:241b.
28. Witzig TE, Gordon LI, Emmanouilides C, et al. Safety and efficacy of Zevalin in four patients with mucosa associated lymphoid tissue (MALT) lymphoma [abstract]. Blood. 2001;98:254b.
29. + non-Hodgkin's lymphoma (NHL): early feasibility report [abstract]. Blood. 2000;96:374b-375b.
30. 90Y Zevalin and high-dose BEAM chemotherapy with hematopoietic progenitor cell transplant in relapsed or refractory B-Cell NHL [abstract]. Blood. 2001;98:677a-678a.
31. Witzig TE, Gordon LI, Wiseman GA, et al. Zevalin radioimmunotherapy is safe and well tolerated in patients with relapsed or refractory, B cell non-Hodgkin's lymphoma (NHL) [abstract]. Blood. 2000;96:731a.
32. Emmanouilides C, Witzig TE, White CA, et al. Zevalin™ Radioimmunotherapy is associated with a low infection risk [abstract]. Blood. 2001; 98:227b-228b.
33. Gordon LI, Wiseman GA, Witzig TE, et al. Zevalin induces transient neutropenia and B-cell depletion but does NOT induce clinically significant hypogammaglobulinemia nor serious infection risk [abstract]. J Clin Oncol. 2000;19:23a.
34. Wiseman GA, Gordon LI, Witzig TE, et al. Zevalin radioimmunotherapy is not associated with significant or prolonged depletion of T cells or natural killer cells [abstract]. Blood. 2000;96:252b.
35. Gordon LI, White CA, Leonard JP, Witzig TE, Multani PS. Zevalin™ radioimmunotherapy is associated with a low incidence of human-anti mouse antibody (HAMA) and human anti-Rituxan® antibody (HACA) response [abstract]. Blood. 2001; 98:228b.
36. Czuczman MS, White CA, Emmanouilides C, et al. Zevalin® radioimmunotherapy in patients with pre-existing host humoral responses [abstract]. Blood. 2001;98:240b.
37. Witzig TE, White CA, Gordon LI, et al. Zevalin™ radioimmunotherapy can be safely administered to patients with relapsed or refractory, B cell non-Hodgkin's Lymphoma (NHL) [abstract]. Blood. 2001;98:606a.
38. Alazraki NP, Leigh BR, Carter WL, et al. Gastrointestinal adverse events associated with Zevalin™ radioimmunotherapy do not correlate with nuclear medicine imaging findings [abstract]. Blood. 2001;98:226b.
39. 90yttrium ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol. 2002;20: 3885-3890.
40. Gordon LI, Witzig TE, Schilder R, et al. High-dose therapy can be safely and successfully administered after Zevalin treatment [abstract]. J Clin Oncol. 2001;20:232b.
41. Saleh F, Saleh M, Witzig T, et al. Rituximab administration subsequent to ibritumomab tiuxetan (Zevalin) radioimmunotherapy [abstract]. Proc ASCO. 2002;21:8a.
42. Wiseman GA, Leigh BR, Witzig TE, Gansen D, White CA. Family members of patients receiving Zevalin® radioimmunotherapy do not receive radiation exposure above background levels [abstract]. Blood. 1997;98:236b-237b.
43. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91:1644-1652.
44. Kolstad A, Tuck MK, Kaminski MS. Characterization of the apoptotic process initiated by ligation of CD20 by the mouse monoclonal antibody anti-B1 in the Burkitt's lymphoma cell line Ramos [abstractl. Blood. 1999;94:87a.
45. Cardarelli P, Quinn M, Colcher D, Bebbington C, Yarranton G. Induction of apoptosis and inhibition of cellular proliferation of human B-cell lines by anti-CD20 antibodies, tositumomab and rituximab [abstract]. Proc Amer Soc Clin Oncol. 2001;20: 275a.
46. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125:1678-1685.
47. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with [I-131] anti-B1 antibody. N Engl J Med. 1993;329: 459-465.
48. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14:1974-1981.
49. Kaminski MS, Estes J, Zasadry KR, et al. Radioimmunotherapy with iodine 131 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259-1266.
50. Kaminski MS, Press OW, Lister TA, Valente NK, Kroll S, Tidmarsh G. Iodine I131 tositumomab for patients with small lymphocytic lymphoma (SLL): overall clinical trial experience [abstract]. Blood. 1999;94:88a-89a.
51. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2000;18:1316-1323.
52. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of Bexxar (Iodine I 131 tositumomab) for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001;19:3918-3928.
53. Horning SJ, Lucas JB, Younes A, et al. Iodine-131 tositumomab for non-Hodgkin's lymphoma (NHL) patients who progressed after treatment with rituximab: results of a multicenter phase II study [abstract]. Blood. 2000;96:508a.
54. Gockerman J, Gregory S, Harwood S, et al. Interim efficacy results of Bexxar in a large multicenter expanded access study [abstract]. Proc ASCO. 2001;20:285a.
55. Kaminski MS, Gribben T, Estes J, et al. I-131 anti-B1 antibody for previously untreated follicular lymphoma (FL): clinical and molecular remissions [abstract]. Proc ASCO. 1998;17:2a.
56. Leonard JP, Zelenetz AD, Vose JM, et al. Iodine 131 tositumomab for patients with low-grade or transformed low-grade NHL: complete response data [abstract]. Blood. 2000;96:728a.
57. Shipp MA, Harrington DP, Anderson JR, et al. Development of a predictive model for aggressive lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
58. Gregory SA, Coleman M, Ali A, O'Brien TM, et al. Efficacy and safety of Bexxar in the expanded access study: interim report from two institutions [abstract]. Blood. 2000;96:238b.
59. Kaminski MS, Estes J, Tuck M, et al. Iodine I 131 tositumomab for previously untreated follicular lymphoma (FL) [abstract]. Proc ASCO. 2000;19: 5a.
60. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol. 1998;16: 3270-3278.
61. Press OW, Eary JF, Gooley T, et al. Aphase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96:2934-2942.
62. Bennett JM, Zelenetz AD, Press OW, et al. Incidence of myelodysplastic syndromes (tMDS) and acute myeloid leukemia (tAML) in patients with low-grade non-Hodgkin's lymphoma (LG-NHL) treated with Bexxar™ [abstract]. Blood. 2001;98: 335a.
63. Kaminski MS, Tuck M, Fang Y, Colcher D, Valente N, Nieder M. Development of HAMA after Bexxar™ therapy does not preclude treatment with rituximab [abstract]. Blood. 2000;96:734a.
64. Leonard JP, Coleman M, Kostakoglu L, et al. Fludarabine monophosphate followed by iodine I 131 tositumomab for untreated low-grade and follicular non-Hodgkin's lymphoma (NHL) [abstract]. Blood. 1999;94:90a.
65. Valente NK, Kaminski MS, Knox SJ, et al. Subsequent therapy can be administered following treatment with Iodine-131 anti-B1 antibody in patients with non-Hodgkin's lymphoma (NHL) [abstract]. Ann Oncol. 1999;10:33.
66. Kaminski M, Bahm V, Estes J, Ratanatharathorn V. Tolerance of treatment subsequent to frontline Bexxar™ (tositumomab and iodine 1131 tositumomab) in patients (Pts) with follicular lymphoma [abstract]. Blood. 2001;98:603a.
67. Ratanatharathorn V, Uberti JP, Ayash L, Estes J, Silver S, Kaminski M. Hematopoietic stem cell transplantation (HSCT) in lymphoma patients receiving prior therapy with tositumomab and iodine 131 tositumomab (Bexxar™) [abstract]. Blood. 2001;98:200a.
68. Siegel JA, Kroll S, Regan D, Kaminski MS, Wahl RL. A practical methodology for patient release after tositumomab and 131I-tositumomab therapy. J Nucl Med. 2002;43:354-363.
69. Linden P, Tennvall J, Cavallin-Stahl E, et al. Radioimmunotherapy using 131 I-labeled anti-CD22 monoclonal antibody (LL2) in patient with previously treated B-cell lymphomas. Clin Cancer Res. 1999;5:3287s-3291s.
70. O'Donnell RT, Shen S, DeNardo SJ, et al. A phase I study of 90Y-21T-BAD-LYM-1 in patients with non-Hodgkin's lymphoma. Anticancer Res. 2000;20:3647-3655.
71. 67Copper-2-iminothiolane-6-[p-(bromoacetamido) benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma. Clin Cancer Res. 1999;5:3330s-3336s.
72. O'Donnell RT, DeNardo GL, Kukis DL, et al. A clinical trial of radioimmunotherapy with 67Cu-21T-BAT-Lym-1 for non-Hodgkin's lymphoma. J Nucl Med. 1999;40:2014-2020.
73. 67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. Clin Cancer Res. 1999;5: 533-541.
74. 211At-rituximab against non-Hodgkin's lymphoma cells. Br J Cancer. 2000;83:1375-1379.
75. Ma D, McDevitt MR, Barendswaard E, et al. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Leukemia. 2002;16:60-66.
76. DeNardo GL, DeNardo SJ, Goldstein DS, et al. Maximum-tolerated dose, toxicity, and efficacy of 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol. 1998;16:3246-3256.
77. Davis TA, Griffo-López AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of retreatment. J Clin Oncol. 2000;18:3135-3143.
78. Grillo-López AJ, Cheson BD, Horning SJ, et al. Response criteria for NHL: importance of "normal" lymph node size and correlations with response rates. Ann Oncol. 2000;11:399-408.
79. Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of Cd20-expressing lymphoma xenografts. Blood. 2001;98:2535-2543.
80. Weiden PL, Breitz HB, Press O, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm. 2000; 15:15-29.
81. Cheson BD, Fisher RI. Monoclonal antibody therapy of hematologic malignancies-future directions. In: Cheson BD, ed. Monoclonal Antibody Therapy of Hematologic Malignancies. Abington, Oxfordshire, England: Darwin Scientific Publications; 2001:259-273.
82. Cheson BD. Some like it hot! J Clin Oncol. 2001; 19:3908-3911.
83. Press OW, Unger JM, Braziel R, et al. A phase II trial of CHOP followed by Bexxar™ (tositumomab and iodine-131-tositumomab) for treatment of newly diagnosed follicular non-Hodgkin's lymphomas (SWOG 9911)[abstract]. Blood. 2001;98: 843a.